Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06665425

PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers

An Open-label, Crossover, Phase 1 Clinical Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Drug-drug Interactions and Safety/Tolerability of Epaminurad and C2406 When Co-administered in Healthy Adults

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
18 (estimated)
Sponsor
JW Pharmaceutical · Industry
Sex
All
Age
19 Years – 50 Years
Healthy volunteers
Accepted

Summary

A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and C2406 in Healthy Volunteers

Conditions

Interventions

TypeNameDescription
DRUGEpaminurad 9 mgPeriod 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
DRUGC2406Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406

Timeline

Start date
2025-03-24
Primary completion
2025-05-02
Completion
2025-09-07
First posted
2024-10-30
Last updated
2025-09-09

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT06665425. Inclusion in this directory is not an endorsement.